TIANJIN DEV (00882.HK): Interim Profit Attributable to Shareholders HK$ 325.2 Million, Interim Dividend HK 5.18 Cents

NewTimeSpace · 2026/09/18 07:36 · By Boyuan Chen

On 18 September 2026, TIANJIN DEV (00882.HK) published its 2026 interim report, reporting revenue of approximately HK$ 1,657,990,000, down approximately 3.5% year on year, profit attributable to owners of the Company of approximately HK$ 325,222,000, and an interim dividend of 5.18 HK cents per share.

Key Highlights:

Profit for the period was approximately HK$ 404,783,000 and basic earnings per share were 30.32 HK cents (first half of 2025: 32.11 HK cents); the interim dividend of 5.18 HK cents per share is payable on 30 October 2026 to shareholders on the register as at 25 September 2026.
The pharmaceutical segment recorded revenue of approximately HK$ 811,700,000, down 6%, and segment profit of approximately HK$ 72,800,000, with the prior-year period flattered by a special dividend of HK$ 303,100,000 from Tasly Group.
As at 30 June 2026, total cash on hand was approximately HK$ 6,834,100,000 and total bank loans approximately HK$ 1,958,900,000, with a debt-to-equity ratio of approximately 14.4%; the disposal of the entire interest in Bailee Finance Leasing was completed on 22 May 2026.

NewTimeSpace News: On 18 September 2026, Tianjin Development Holdings Limited (stock code: 00882) published its 2026 interim report. For the six months ended 30 June 2026, revenue was approximately HK$ 1,657,990,000, down approximately 3.5% year on year, and gross profit was approximately HK$ 498,684,000, down approximately 9.0%. Profit for the period was approximately HK$ 404,783,000, of which profit attributable to owners of the Company was approximately HK$ 325,222,000, down approximately 5.6%, and basic earnings per share were 30.32 HK cents, compared with 32.11 HK cents a year earlier.

The Board declared an interim dividend of 5.18 HK cents per share (first half of 2025: 5.18 HK cents per share), payable on 30 October 2026 to shareholders on the register of members on 25 September 2026.

By business segment, the pharmaceutical segment recorded revenue of approximately HK$ 811,700,000, down 6%, and segment profit of approximately HK$ 72,800,000, compared with HK$ 377,900,000 a year earlier, mainly because the prior-year period included a special dividend of HK$ 303,100,000 paid by Tasly Group. Within the utilities segment, the thermal power company recorded revenue of approximately HK$ 549,100,000, down 3.5%, while the water supply company recorded revenue of approximately HK$ 144,000,000.

As at 30 June 2026, the Group's total cash on hand was approximately HK$ 6,834,100,000 and total bank loans were approximately HK$ 1,958,900,000, with a debt-to-equity ratio of approximately 14.4%. Tianjin Taikang Investment Co., Ltd., a subsidiary 82.74% owned by the Company, completed the disposal of its entire interest in Bailee Finance Leasing on 22 May 2026, and the Group recognised a gain of approximately HK$ 47,900,000.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

NewTimeSpace TIANJIN DEV 00882.HK